CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Schrodinger Q3 revenue beats expectations on milestone payment

By Reuters News


Overview

  • Computational molecular discovery platform's Q3 revenue rose 19% yr/yr, beating analyst expectations

  • Net loss widened to $37.7 mln from $32.8 mln last year

  • Drug discovery revenue rose, helped by milestone payment from Structure Therapeutics


Outlook

  • Schrodinger raises 2026 ACV guidance to $222 mln-$232 mln from $218 mln-$228 mln

  • Company lifts 2026 drug discovery revenue outlook to $75 mln-$85 mln from $65 mln-$75 mln

  • Operating expenses for 2026 expected to be less than in 2025


Result Drivers

  • MILESTONE PAYMENT - Drug discovery revenue increase was primarily due to a milestone payment from Structure Therapeutics

  • HOSTED SOFTWARE TRANSITION - Software gross margin fell 2% as company continued transition to hosted licenses

  • OPERATING EXPENSES - Operating expenses decreased 13% yr/yr, contributing to improved operating results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$64.49 mln

$47.26 mln (5 Analysts)

Q3 Net Loss

$37.71 mln

Q3 Gross Profit

$38.25 mln

Q3 Operating Expenses

$64.38 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy"

  • Wall Street's median 12-month price target for Schrodinger Inc is $24.00, about 11.7% below its November 3 closing price of $27.18


Reuters Recommended Reads

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength

  • Nov 2 - Recursion Pharmaceuticals Q3 net loss narrows more than expected on lower costs

  • Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.